NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) ...
Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS NASHVILLE, ...
Please provide your email address to receive an email when new articles are posted on . Eye care pharmaceutical company Harrow announced the completed transfer of new drug applications for Flarex, ...
FORT WORTH, Texas, March 2, 2020 /PRNewswire/ -- Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results